Aggrecan G3, Polyclonal, Invitrogen
Rabbit Polyclonal Antibody
Manufacturer: Invitrogen PA11745
Aggrecan is a member of large, aggregating proteoglycans (also including, versican, brevican and neurocan) found in articular cartilage. Aggrecan is composed of three major domains: G1, G2, and G3. Between the G1 and G2 domains there is an interglobulin region (IGD). The IGD region is the major site of cleavage by specific proteases like metalloproteinases (MMP’s) and aggrecanase. Aggrecan cleavage has been associated with a number of degenerative diseases including rheumatoid arthritis and osteoarthritis.The G3 domain is a complicated region produced by alternative splicing of exons in post-transcriptional processes. The human G3 domain consists of three modules and articular cartilage contains a mixture of the alternatively spliced G3 modules. G3 has been shown to facilitate glycosaminoglycan (GAG) attachment and overall aggrecan processing. The G3 domain is central to aggrecan turnover and function in cartilage.PA1-1745 detects human, rat, mouse, bovine, and canine aggrecan G3.PA1-1745 has been successfully used in Western blot procedures. By Western blot, this antibody detects an ~350kDa protein representing the aggrecan G3 domain on the full length core.The PA1-1745 immunogen is a synthetic peptide corresponding to residues C D(2277) G H P M Q F E N W R P N Q P D N(2293) of human aggrecan.. This antibody is also referred to as anti-G3.
|Synthetic peptide corresponding to residues C D(2277) G H P M Q F E N W R P N Q P D N(2293) of human aggrecan.|
|Store at -20°C, Avoid Freeze/Thaw Cycles|
|PBS with 1mg/mL BSA and 0.05% sodium azide|
|P13608, Q28343, P16112, Q61282, P07897|
|AGC1, AGCAN, CSPG1, CSPGCP, MSK16, SEDK|
|Bovine, Canine, Human, Murine, Rat|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok